4-甲基-N-[4-[(4-甲基-1-哌嗪基)甲基]-3-(三氟甲基)苯基]-3-[2-(1H-吡唑并[3,4-b]吡啶-5-基)乙炔基]苯甲酰胺

GZD824是新型口服的Bcr-Abl野生型和T315I突变型抑制剂,IC50分别为0.34和0.68nM。

信号通路 >> 蛋白酪氨酸激酶 >> BCR-ABL

研究领域 >> 癌症

[1]. Ren X, Pan X, Zhang Z, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against

诺考达唑 | 阿思尼布 | (2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基丁基]-2-丙烯酰胺 | 巴氟替尼 | N-[3-叔丁基-1-(喹啉-6-基)-1H-吡唑-5-基]-N'-[2-氟-4-[(2-(甲基氨基甲酰基)吡啶-4-基)氧]苯基]脲 | [4-[2-(1H-吲唑-3-基)乙烯基]苯基]-1-哌嗪基甲酮 | AST 487 | PD173955 | N4-(5-环丙基-1H-吡唑-3-基)-N2-[[3-异丙基-5-异恶唑基]甲基]-6-(4-甲基-1-哌嗪基)-2,4-嘧啶二胺 | 5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑啉-2,4-二酮 | 3-[6-[[4-(三氟甲氧基)苯基]氨基]-4-嘧啶基]苯甲酰胺 | GNF-7 | 4-[(4-甲基-1-哌嗪基)甲基]-N-[6-甲基-5-[[4-(3-吡啶基)-2-嘧啶基]氨基]-3-吡啶基]-3-(三氟甲基)苯甲酰胺 | GNF-5 | 拉多替尼